Hereditary amyloidosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:444116
Who is this for?
Show terms as
3FDA treatments4Active trials9Specialists8Treatment centers9Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hereditary Amyloidosis is treated with 3 medications in our database, including AMVUTTRA, Onpattro, WAINUA. 3 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Alnylam, AstraZeneca. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Hereditary Amyloidosis treatment below.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

University Hospital, Montpellier — NA

TrialNOT YET RECRUITING
Feb 2026A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

Mayo Clinic

TrialNOT YET RECRUITING
Feb 2026Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

Virginia Commonwealth University

TrialNOT YET RECRUITING
Dec 2025Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

University of Texas Southwestern Medical Center

TrialRECRUITING
Nov 2025The Eplontersen Pregnancy and Lactation Outcomes Study

AstraZeneca

TrialRECRUITING
Nov 2025Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Seoul St. Mary's Hospital — PHASE4

TrialNOT YET RECRUITING
Nov 2025To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Eidos Therapeutics, a BridgeBio company — PHASE3

TrialNOT YET RECRUITING
Sep 2025US Benchmarking Clinical Study

eMyosound SAS

TrialRECRUITING
Jun 2025To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

Qilu Pharmaceutical Co., Ltd. — PHASE4

TrialRECRUITING
Jan 2025An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

Yale University

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

Onpattro

patisiran· Alnylam

* Patient Copay Amount: Not Publicly Available * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Patients must have commercial insurance and be residents of the U

AMVUTTRA

VUTRISIRAN· Alnylam

* Patient Copay Amount: $0 for most eligible patients * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Must have commercial insurance; not eligible for patients

WAINUA

EPLONTERSEN· AstraZeneca

* Patient Copay Amount: As little as $0 per month * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Must have commercial insurance, a valid prescription for WAINU

Clinical Trials

4 recruitingView all trials with filters →
Phase 31 trial
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3
Active
· Sites: Buenos Aires; Buenos Aires +14 more · Age: 1885 yrs
Phase 21 trial
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Phase 2
Actively Recruiting
· Sites: Portland, Oregon · Age: 1890 yrs
Other2 trials
Phenotypic Manifestations of Hereditary ATTR Amyloidosis
Enrolling by Invitation
PI: Mauricio MT Tomei, MD (Hospital 9 de Julio de Las Breñas) · Sites: Charata, Chaco Province · Age: 2099 yrs
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
Actively Recruiting
· Sites: Pavia · Age: 1899 yrs

Specialists

9 foundView all specialists →
AM
Anissa MEGZARI
Specialist
PI on 15 active trials1 Hereditary amyloidosis publication
SM
Sharmila Dorbala, MD
BOSTON, MA
Specialist
PI on 3 active trials
CK
Chafic Karam
PORTLAND, OR
Specialist
PI on 1 active trial
RO
Robert E O'Donnell
Specialist
PI on 1 active trial
MT
Mauricio MT Tomei
Specialist
PI on 1 active trial
MB
Merrill D. Benson
Specialist
PI on 1 active trial
PS
Phillip Scheinberg
BETHESDA, MD
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

9 grants

AstraZeneca Access 360

AstraZeneca

Access 360 provides support services for US patients prescribed FASLODEX to help navigate insurance coverage and out-of-pocket cost concerns. The program offers resources for patient affordability and assistance with accessing AstraZeneca medications.

Apply ↗

AstraZeneca Oncology Patient Transportation Program

AstraZeneca

Good Days provides financial and planning assistance for ground and air transportation, lodging, and parking for patients traveling at least 50 miles for medical care. Eligibility is based on medical necessity as determined by the patient's prescribing physician.

Apply ↗

AstraZeneca Access 360™

AstraZeneca

Apply ↗

AstraZeneca Access 360

AstraZeneca

Apply ↗

AstraZeneca Co Pay Savings & Assistance Programs

AstraZeneca

Apply ↗

AstraZeneca Access 360

AstraZeneca

Apply ↗

AstraZeneca Patient Support

AstraZeneca

Apply ↗

AstraZeneca Patient Assistance and Reimbursement Guide

AstraZeneca

Apply ↗

AstraZeneca Savings and Insurance Support

AstraZeneca

Apply ↗

Community

Open Hereditary amyloidosisForum →

No community posts yet. Be the first to share your experience with Hereditary amyloidosis.

Start the conversation →

Latest news about Hereditary amyloidosis

Disease timeline:

New recruiting trial: To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Exploring Biomarkers in Hereditary Transthyretin Amyloidosis

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Comprehensive Program for Hereditary Transthyretin Amyloidosis

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Phenotyping and Characterization of wtATTR-CM (TRACE 1)

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Dominantly Inherited Alzheimer Network (DIAN)

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Registre HEAR, Healthcare European Amyloidosis Registry

A new clinical trial is recruiting patients for Hereditary amyloidosis

New recruiting trial: Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

A new clinical trial is recruiting patients for Hereditary amyloidosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hereditary amyloidosis

What is Hereditary amyloidosis?

Hereditary Amyloidosis is treated with 3 medications in our database, including AMVUTTRA, Onpattro, WAINUA. 3 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Alnylam, AstraZeneca. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Hereditary Amyloidosis treatment below.

At what age does Hereditary amyloidosis typically begin?

Typical onset of Hereditary amyloidosis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Hereditary amyloidosis?

Yes — 4 recruiting clinical trials are currently listed for Hereditary amyloidosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hereditary amyloidosis?

9 specialists and care centers treating Hereditary amyloidosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Hereditary amyloidosis?

3 FDA-approved treatments and 1 patient support program are currently tracked on UniteRare for Hereditary amyloidosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.